Autolus Therapeutics (AUTL) Accounts Payables (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Accounts Payables for 9 consecutive years, with $3.1 million the latest figure, recorded in Q4 2025.

• Quarterly Accounts Payables rose 56.58% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (up 56.58% YoY) and the FY2025 annual result came in at $3.1 million, up 56.58% from the prior year.
• Accounts Payables declined to $3.1 million in Q4 2025 per AUTL's latest filing, from $11.0 million in the prior quarter.
• Over the last five years, Accounts Payables for AUTL reached as high as $11.0 million in Q3 2025 and fell as low as $103000.0 in Q4 2023.
• A 5-year average of $2.1 million and a median of $1.3 million in 2021 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 93.23% — and 2023, when it jumped 2293.83%.
• Year by year, Accounts Payables stood at $431000.0 in 2021, then climbed by 23.2% to $531000.0 in 2022, then slumped by 80.6% to $103000.0 in 2023, then soared by 1811.65% to $2.0 million in 2024, then soared by 56.58% to $3.1 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $3.1 million, $11.0 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.